{
    "id": 15108,
    "fullName": "MS4A1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MS4A1 positive indicates the presence of the MS4A1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 931,
        "geneSymbol": "MS4A1",
        "terms": [
            "MS4A1",
            "B1",
            "Bp35",
            "CD20",
            "CVID5",
            "LEU-16",
            "MS4A2",
            "S7"
        ]
    },
    "variant": "positive",
    "createDate": "12/11/2015",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17568,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, Rituxan (rituximab) treatment resulted in an overall response rate of 57% (21/37, 5 complete response, 16 partial response) in patients with relapsed or refractory, low-grade or follicular, MS4A1 (CD20)-positive, B-cell non-Hodgkin lymphoma (PMID: 10442187).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 897,
                "therapyName": "Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15635,
                    "pubMedId": 10442187,
                    "title": "Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10442187"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12848,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical trial that supported FDA approval, treatment with Rituxan (rituximab) resulted in a response rate of 48% in patients (n=166) with relapsed low-grade or follicular, MS4A1 (CD20)-positive, B-cell non-Hodgkin lymphoma (PMID: 9704735).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 897,
                "therapyName": "Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10804,
                    "pubMedId": 9704735,
                    "title": "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9704735"
                },
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17573,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PRIMA) that supported FDA approval, Rituxan (rituximab) maintenance therapy improved progression-free survival rate (74.9% vs 57.6%, HR=0.55, p<0.0001) compared to observation only in patients with previously untreated follicular lymphoma who achieved complete or partial response to first-line chemotherapy (PMID: 21176949; NCT00140582).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 897,
                "therapyName": "Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15636,
                    "pubMedId": 21176949,
                    "title": "Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21176949"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17575,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Rituxan (rituximab) treatment as induction or maintenance therapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) significantly improved 2-year progression-free survival rate (76% vs 61%, p=0.009) compared to CHOP alone in elderly patients with untreated, MS4A1 (CD20)-positive, diffuse large B-cell lymphoma (PMID: 16754935).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 2195,
                "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                "synonyms": "Rituximab + CHOP|RCHOP"
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15645,
                    "pubMedId": 16754935,
                    "title": "Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16754935"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17574,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MInT) that supported FDA approval, Rituxan (rituximab) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy resulted in improved 3-year event-free survival (79% vs 59%) and 3-year overall survival (93% vs 84%) compared to chemotherapy alone in patients with untreated, MS4A1 (CD20)-positive, diffuse large B-cell lymphoma with good prognosis (PMID: 16648042; NCT00064116).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 2195,
                "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                "synonyms": "Rituximab + CHOP|RCHOP"
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15644,
                    "pubMedId": 16648042,
                    "title": "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16648042"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15964,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Venetoclax (ABT-199) and the MS4A1 antibody, MT-3724, resulted in a synergistic effect, demonstrating growth inhibition and induced apoptosis in mantle cell lymphoma cell lines in culture (PMID: 29559616).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 7833,
                "therapyName": "MT-3724 + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14076,
                    "pubMedId": 29559616,
                    "title": "The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559616"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19644,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DRL_RI demonstrated comparable pharmacokinetic, safety, immunogenicity, and efficacy to Rituxan (rituximab) in patients with MS4A1 (CD20)-positive diffuse large B-cell lymphoma, resulted in an overall response rate of 82.0% (50/61), compared to 84.8% (56/66) in Rituxan (rituximab)-treated group (PMID: 31809224).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 9117,
                "therapyName": "DRL_RI",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17384,
                    "pubMedId": 31809224,
                    "title": "Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31809224"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12124,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BTCT4465A efficiently killed leukemic B cells derived from chronic lymphocytic leukemia patients in culture and in patient-derived xenograft (PDX) animal models (PMID: 25972002).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 6304,
                "therapyName": "BTCT4465A",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10091,
                    "pubMedId": 25972002,
                    "title": "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25972002"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20849,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CD20 CAR T-cells induced cytotoxicity when co-cultured with MS4A1-expressing Burkitt lymphoma cell lines, and reduced tumor growth and increased survival in a cell line xenograft model (PMID: 25492700).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 9486,
                "therapyName": "CD20 CAR T-cells",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18080,
                    "pubMedId": 25492700,
                    "title": "Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25492700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15960,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the MS4A1 antibody, MT-3724, resulted in cell growth inhibition in 6/8 mantle cell lymphoma cell lines resistant to Imbruvica (ibrutinib) and led to decreased tumor volume and increased overall survival compared to control in a mantle cell lymphoma patient-derived xenograft (PDX) model, also resistant to Imbruvica (ibrutinib) (PMID: 29559616).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 7831,
                "therapyName": "MT-3724",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14076,
                    "pubMedId": 29559616,
                    "title": "The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559616"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20933,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDA-201 and Rituxan (rituximab) combination therapy demonstrated safety and preliminary efficacy, resulted in an overall response rate of 71% (5/7, 3 complete response (CR), 3 partial response (PR)) in patients with relapsed/refractory MS4A1 (CD20)-positive non-Hodgkin lymphoma, with a median duration of response of 12 and 5 months in CR and PR patients, respectively (Blood (2019) 134 (Supplement_1): 777).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 9516,
                "therapyName": "GDA-201 + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 60060,
                "name": "non-Hodgkin lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18191,
                    "pubMedId": null,
                    "title": "Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)",
                    "url": "https://doi.org/10.1182/blood-2019-130476"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17564,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BO17072) that supported FDA approval, addition of Rituxan (rituxumab) to Fludara (fludarabine) and Cytoxan (cyclophosphamide) combination treatment improved progression-free survival (30.6 vs 20.6 months, HR=0.65, p<0.001) in patients with with previously treated, MS4A1 (CD20)-positive chronic lymphocytic leukemia (PMID: 20194844; NCT00090051).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 2339,
                "therapyName": "Cyclophosphamide + Fludarabine + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15633,
                    "pubMedId": 20194844,
                    "title": "Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20194844"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12852,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ML17102) that supported FDA approval, addition of Rituxan (rituxumab) to Fludara (fludarabine) and Cytoxan (cyclophosphamide) combination treatment improved progression-free survival (51.8 vs 32.8 months) in patients with treatment-naive, MS4A1 (CD20)-positive chronic lymphocytic leukemia (PMID: 20888994; NCT00281918).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 2339,
                "therapyName": "Cyclophosphamide + Fludarabine + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10806,
                    "pubMedId": 20888994,
                    "title": "Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20888994"
                },
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15963,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Imbruvica (ibrutinib) and MS4A1 antibody, MT-3724, resulted in a synergistic effect, inducing apoptosis in Imbruvica (ibrutinib)-resistant mantle cell lymphoma cell lines in culture (PMID: 29559616).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 7832,
                "therapyName": "Ibrutinib + MT-3724",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14076,
                    "pubMedId": 29559616,
                    "title": "The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559616"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15367,
            "profileName": "MS4A1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32250,
            "profileName": "CD5 pos MS4A1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}